In line with this, a search for factors that interfere with MDM2 inhibition identified MDMX as one of the main drivers of resistance [101], and MDMX overexpression correlates with poor response to nutlin-3a in chronic lymphocytic leukaemia (CLL) cells [102] but not in AML cells [87]. Here, MDM2 is linked to B-cell chronic lymphocytic leukemia.